RVTYNEUTRAL

RVTY EV/EBITDA Analysis

16.8x

Higher than 56% of Healthcare sector peers

Updated 117h ago·SEC filings & market data

Key Takeaway

Revvity's current EV/EBITDA of 16.8x means the company is valued at 16.8 times its earnings before interest, taxes, depreciation, and amortization (a proxy for cash operating profit), giving a sense of how expensive the stock is relative to its cash earnings.

Sector Performance

56th percentile

RVTY

16.8x

Sector Median

14.8x

Sector Avg

27.8x

Prior Period

17.4x(Jul 2026)

↑ Improving

📊

Deep Analysis

This ratio sits above the Healthcare sector median of 15.3x, placing Revvity in the 58th percentile among its sector peers — meaning it is more expensive than 58% of comparable companies. The metric has been stable over the last eight quarters: it rose 5.3% year-over-year but fell 3.6% quarter-over-quarter, indicating no sharp directional shift. A valuation above the sector median combined with a stable trend suggests moderate pricing without clear signs of overvaluation or undervaluation, implying average risk and limited short-term opportunity. This profile directly supports the overall NEUTRAL verdict, as the metric shows neither a compelling discount nor an excessive premium relative to peers.

Frequently Asked Questions

What does the EV/EBITDA tell investors about RVTY?

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.

How is the EV/EBITDA calculated?

EV/EBITDA is calculated as: Enterprise Value / EBITDA.

How does RVTY's EV/EBITDA compare to its sector?

RVTY's EV/EBITDA of 16.8x compares to a Healthcare sector median of 14.8x, placing it in the 56th percentile.

Who are RVTY's closest peers by EV/EBITDA?

The closest Healthcare peers by EV/EBITDA include: CAH (14.8x), AMGN (14.0x), DGX (13.6x), ALGN (13.5x), BIO (17.3x).

📚

Learn More About EV/EBITDA

EV/EBITDA Explained: The Valuation Metric Pro Investors Actually Use

Learn what EV/EBITDA is, why it beats P/E for capital-heavy companies, typical sector ranges, and key limitations every serious investor should know.

The Formula

Enterprise Value / EBITDA

Why It Matters

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.